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Abstract 
Background 
Clostridium difficile infection (CDI) is not generally reported to public health authorities in 
the Middle East and its true prevalence remains largely unknown. The aims of this study were 
to determine the prevalence of CDI and its associated ribotypes among C. difficile isolates in 
Qatar. Influence of age and correlation with other risk factors e.g. proton pump inhibitor use, 
antibiotic use, existence of chronic conditions, etc was also investigated for CDI positive 
patients. 
Methods 
A total of 1,532 patients with suspected CDI were recruited from two hospitals between 2011 
and 2012. C. difficile was identified using glutamate dehydrogenase (GDH) lateral flow assay 
and toxins A and B Enzyme Immunoassay (EIA). The C. difficile positive samples were then 
cultured for PCR-ribotyping. 
Results 
122 of the 1,532 (7.9%) samples from individual patients were identified as C.difficile 
positive; and 79 of these were viably cultured (~65%). From these, 36 different PCR 
ribotypes were isolated, of which strains 258 (6 [7.6%]), 01/014/046 (5 [6.3%]), and 
011/053/056/107 (4 [5%]) were the most prevalent. The prevalence of PCR-ribotype 027 was 
1.3% (n = 1). An age of ≥65 years and treatment with proton pump inhibitors correlated with 
higher frequency of CDI. Treatment with third generation cephalosporins (50 [41%]) and 
piperacillin/tazobactam antibiotics (55 [45.1%]) was most frequently associated with CDI. 
Conclusion 
The most common C. difficile ribotype identified in Qatar was 258, which is different from 
those found in North America, Europe and Asia. The prevalence of CDI was higher in Qatar 
than Europe; though comparable to other Middle Eastern countries. These findings 
underscore the importance of local surveillance to detect and control C. difficile infection. 
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Background 
Infection with Clostridium difficile is a common cause of diarrhoea, especially diarrhoea 
associated with a history of antibiotic use [1]. C. difficile has been identified as the major 
pathogen implicated in nosocomial diarrhoea arising >72 hours after admission among 
patients receiving antibiotics [2]. The infection can range from mild diarrhoea to severe 
pseudomembranous colitis. Risk factors for C. difficile infection (CDI) include antibiotic 
exposure, hospitalisation, and advanced age [1]. 
The epidemiology and microbiology of CDI varies according to regional differences. In 
North America and Europe, the epidemiology of CDI is well-documented. For example, the 
clindamycin-resistant ribotype 017 strain of apparent clonal origin has been the cause of 
epidemics in Canada, the Netherlands, Ireland and Asia [3-7]. However, ribotypes 027 and 
078, which are the main causes of outbreaks in other regions of the world, appear to be rare in 
Asian countries [7]. It is important to assess CDI in the Arab world, where limited data are 
available on both CDI prevalence and its ribotypes, despite over-prescription of antibiotics in 
this region [8-12]. 
In Qatar, CDI is not necessarily reported to the public health authorities and its true 
prevalence remains unknown. This may be due to the poor awareness of antibiotic resistance 
and its association with CDI among physicians, thus highlighting the need for increased 
awareness and surveillance of CDI in Qatar and characterizing the circulating strains. 
The aim of the present study is to investigate the epidemiology of CDI in patients admitted to 
Hamad General Hospital and Al-Khor Hospital in Qatar and identify the specific ribotypes 
associated with CDI in Qatar. In addition, the influence of age and correlation with other 
factors such as proton pump inhibitor use, antibiotic use, existence of chronic conditions, etc 
was also investigated. 
Methods 
Patients 
From October 2011 to August 2012, consecutive patients with suspected CDI admitted to 
Hamad General Hospital and Al-Khor Hospital, Qatar, were included in the study. Both of 
these hospitals are part of the Hamad Medical Corporation, an academic institute, which 
comprises seven hospitals and a total of 2,070 beds. Hamad General Hospital is a 603-bed 
hospital, serving the population of Doha city. Its services include trauma & emergency 
medicine, paediatrics, critical care, specialised surgery, specialised medicine, laboratory 
medicine and radiology services, The hospital treats between 1,200 and 1,500 patients on 
average per day. Al-Khor Hospital is a 149-bed community hospital serving Northern Qatar. 
The hospital services include emergency medicine, general surgery, orthopedics, ENT, 
urology, dentistry, endocrine medicine, gastroenterology, dialysis, psychiatry, paediatric 
medicine, obstetrics and gynecology and general intensive care. 
Recruited patients included those that were admitted to the hospital with diarrhoea and those 
who developed diarrhoea during hospitalisation. The inclusion criteria were: presence of 
diarrhoea (watery, loose or unformed stool passed at a frequency of three times or more 
within 24 hours); recent (within the last 3 months) antibiotic exposure (as recent antibiotics 
exposure has been linked to increased risk of CDI); abdominal pain; fever; and a distinctive 
foul stool odour. Exclusion criteria included: Children ≤12 months of age, no recent (within 3 
months) antibiotic exposure; gastrointestinal symptoms without diarrhoea. Patients were not 
included in the study more than once if they had recurrent symptoms. 
Hospital acquired diarrhoea was defined as diarrhoea which developed ≥48 hours after 
admission. Community-acquired diarrhoea was defined as diarrhoea, which developed before 
48 hours of admission. CDI was defined as diarrhoea in a patient with a stool culture positive 
for C. difficile. 
The Research Ethical Committee of Hamad Medical Corporation, Qatar approved the study. 
Informed consent was obtained from all participants (or parents in case of children under 16 
yr of age). 
For the patients identified as CDI positive, risk factor analysis for association with specific 
ribotypes was carried out. Factors investigated for correlation with CDI included; proton 
pump inhibitors (PPI) use; older age; medicinal steroid use; non-steroidal anti-inflammatory 
drug (NSAID) use; immunosuppression; chemotherapy; chronic kidney disease 
(CKD);chronic liver disease (CLD); organ transplant; or inflammatory bowel disease (IBD) . 
These factors were primarily identified through patient’s medical history. 
Assessment & isolation of C. difficile 
The stool samples were sent to the Hamad General Hospital Laboratory within a few hours of 
onset of diarrhoea. 
The samples were tested for C.difficile using Glutamate Dehydrogenase (GDH) lateral flow 
assay (Clostridium difficile Quik Chek Complete, Techlab, Alere North America LLC), 
toxins A and B by Enzyme Immunoassay (EIA) and PCR as per the manufacturer’s 
instructions (GeneXpert, Cepheid, CA, USA). 
GDH assay, toxins A and B EIA were first-line screening tests. All samples were then tested 
using PCR. If the PCR did not show consistent results with the initial screening tests during 
the first attempt, it was repeated using new reagents and a new cartridge. If the results were 
negative upon re-testing, the specimen was not considered C.difficile positive. Isolates that 
were shown to be C. difficile negative during the initial screen were not characterised further. 
DNA Extraction 
C. difficile DNA was extracted from blood agar sub-cultured colonies, using a Chelex resin-
based DNA extraction kit (InstaGene Matrix; Bio-Rad, USA). 
PCR Ribotyping 
The C.difficile positive samples identified were cultured in C.difficile selective media 
(Cycloserine Cefoxitin Fructose Agar, CCFA) (bioMérieux, St. Louis, MO) after ethanol 
shock. 
Each specimen (1 ml) was homogenized in 1 ml of absolute alcohol, vortexed to form an 
even suspension, and left to stand at room temperature for up to 1 hr. A 50-75 µl aliquot of 
this deposit was inoculated onto each of the Cycloserine _cefoxitin fructose plate agar to 
obtain isolated bacterial colonies. All media were incubated at 37°C in an anaerobic 
workstation. The cultures were incubated for 48 to 72 h. Tests carried out to positively 
identify C. difficile were the following; morphology, odour (Horse manure odour), 
fluorescence and latex (when necessary). 
PCR-ribotyping was performed on the cultured pure colonies of C. difficile using the 
ribotyping protocol provided by Cambridge University, HPA Microbiology Services, Clinical 
Microbiology Laboratory, UK. 
Briefly, amplification reactions were performed as per Leeds Laboratory Protocol [13], in 45 
µl PCR tubes, containing 34.5 µl RNase/DNase free water; 5.0 µl of 10× RT-PCR reaction 
Mix; 2.25 µl mM MgCl2; 2 µl of 10 mM dNTP; 0.5 µl of 50 pmol/ul, forward and reverse 
primers for the intergenic 16S-23S rRNA Spacer Regions of C. difficile (Forward 5’- 6 FAM 
- GTG CGG CTG GAT CAC CTC CT- 3’ and reverse 5’- CCC TGC ACC CTT AAT AAC 
TTG ACC- 3’); 0.25 µl Taq polymerase; and 5 µl of extracted DNA template (or sterile water 
as a negative control). Amplifications were carried out in a thermal cycler (Touchgene 
Gradient; Techne) for 1 cycle of 2 min at 95°C for denaturation, followed by 30 cycles (1 min 
at 95°C, 1 min at 55°C and 1.5 min at 72°C) and a final extension 7 mins at 72°C. 
Fragment analysis 
ABI-3130 (Applied Biosystem, USA) instrument with POP-gel was used for fragment 
analysis. Peak Scanner software v1.0 was used for data analysis. The peak sizes of all major 
peaks were compared with peaks from reference strains (34 reference strains from a library of 
the most commonly encountered ribotypes in the UK), allowing for deviations ±2 bp. The 
strains with banding patterns that did not match with the reference strains from the UK were 
sent to the Leeds Reference Laboratory, UK for ribotyping. 
Correlation analysis 
Patient records were examined for factors potentially correlating with CDI (age; proton pump 
inhibitor (PPI) use; medicinal steroid use; NSAID use; immunosuppression; chemotherapy; 
chronic kidney disease; chronic liver disease; organ transplant; inflammatory bowel disease). 
Only records of CDI positive patients were examined. The correlation with ribotypes was 
investigated using Crosstab analysis. 
Results 
Patients 
A total of 1,532 patients with suspected CDI were recruited. One hundred and twenty two 
stool samples, out of total 1,532 patients, were C. difficile positive and were selected for 
sample analysis (Table 1). Of the 122 CDI positive patients , 98 (80.3% or 6.4% of 1,532) 
had hospital acquired CDI and 14 (11.5% or 0.9% of 1,532) had community-acquired CDI. 
Medical records for the remaining 10 (8.2%) were not available to categorise them into 
hospital or community-acquired CDI. Amongst the hospital acquired patients, 5.7% (n = 
87/1,532) were from Hamad General Hospital and 0.7% (n = 11/1,532) from Al Khor 
Hospital. Each sample represented an individual patient. All 122 patients were residents of 
Qatar though their ethnic background details are not available. 
Table 1 Baseline patient characteristics of 122 patients with CDI 
Variable Category No. Of subjects n (%) 
Total number of subjects Qatari residents 122 
Gender Males 72 (59%) 
Females 50 (41%) 
Age 1-14 yrs 23 (18.9%) 
15-30 yrs 15 (12.3%) 
31-50 yrs 21 (17.2%) 
51-64 yrs 22 (18%) 
≥ 65 yrs 41 (33.6%) 
Hospital acquired CDI  98 (80.3%) 
Community acquired CDI  14 (11.5%) 
Medical Records not available  10 (8.2%) 
Antibiotics used prior to CDI (some patients were on >1): Tazocin 55 (45.1%) 
Third generation Cephalosporins 50 (41%) 
Amoxicillin 22 (18%) 
Meropenom 20 (16.4%) 
Ciprofloxacin 20 (16.4%) 
Vancomycin 15 (12.3%) 
Co-trimoxazole 10 (8.2%) 
Azithromycin 9 (9.8%) 
Amikacin 6 (7.4%) 
Teicoplanin 4 (3.3%) 
Nitrofurantoin 2 (1.6%) 
Doxycyclin 2 (1.6%) 
Tigecyclin 1 (0.8%) 
Linezolid 1 (0.8%) 
Cloxacillin 1 (0.8%) 
Colistin 1(0.8%) 
Moxifloxacin, 1 (0.8%) 
Ampicillin 1 (0.8%) 
Septrin 1 (0.8%) 
Amygdalin 1 (0.8%) 
PCR ribotyping 
Pure colonies of C. difficile were obtained from only 79 out of 122 CDI positive patient 
samples. In total, 36 different PCR ribotypes (Table 2) were identified among C. difficile 
strains isolated from the 79 successfully cultured strains. Of the 36 C. difficile PCR ribotypes 
isolated, the most frequent ones were 258 (n = 6 [7.6%]), followed by 001/014/046 (n = 5 
[6.3%]), and then 011/053/056/107 (n = 4 [5%]), followed by other PCR ribotypes (51.9%) 
detailed in Table 2. The prevalence of the PCR-ribotype 027 was only 1.3% (n = 1). Hence, 
the PCR ribotypes predominantly found in Qatar during the period of this study were 258 
followed by 001/014/046. Only one ribotype was isolated from each C. difficile colony. 
Table 2 Frequency and percentages of C. difficile ribotypes isolated in Qatar from 2011 
to 2012 (n = 79) 
C. difficile ribotype Frequency N (%) 
258 6 (7.6%) 
001 5 (6.3%) 
014 5 (6.3%) 
046 5 (6.3%) 
011 4 (5.1%) 
053 4 (5.1%) 
056 4 (5.1%) 
107 4 (5.1%) 
015 3 (3.8%) 
017 3 (3.8%) 
023 3 (3.8%) 
183 3 (3.8%) 
016 2 (2.5%) 
081 2 (2.5%) 
084 2 (2.5%) 
087 2 (2.5%) 
097 2 (2.5%) 
103 2 (2.5%) 
104 2 (2.5%) 
003 1 (1.3%) 
004 1 (1.3%) 
020 1 (1.3%) 
027 1 (1.3%) 
078 1 (1.3%) 
106 1 (1.3%) 
116 1 (1.3%) 
126 1 (1.3%) 
174 1 (1.3%) 
186 1 (1.3%) 
193 1 (1.3%) 
216 1 (1.3%) 
248 1 (1.3%) 
353 1 (1.3%) 
436 1 (1.3%) 
095 1 (1.3%) 
Correlating factors with CDI 
Age 
The frequency of CDI in the 122 patients by age groups is shown in Table 1. The frequency 
of ribotypes isolated, from highest to lowest, was: 19 (24%) from the ≥ 65 yr group; 12 
(15%) from the 1-14 yrs group; 12 (15%) from 51-64 yr group; 10 (12.6%) from the 15-30 yr 
group; and 9 (11.3%) from the 31-50 yr group. Both the CDI infection rate and frequency of 
ribotypes isolated were highest in the elderly age group (≥65 yr) (Table 1 for CDI). 
Other correlates 
Table 3 summarises other factors investigated for correlation with CDI. Several factors were 
thought to correlate with CDI, especially use of PPI treatment. Indeed, PPI use was more 
common in patients with CDI than being ≥65 yr of age. However, due to the small sample 
sizes, statistical tests couldn’t be accurately performed on this data. 
Table 3 Factors investigated for correlation with CDI (n = 122) 
Correlating factors Infected with CDI N = 122 (%) Correlating ribotypes 
PPI use*ƚ 65 (53.3%) 014, 258, 046,053, 017 and 001 
Age ≥ 65 yr 41 (33.6%) 107, 001,103, 011,116, 126,015, 017, 183, 186, 003,046, 053, 056, 078, 081, 084 
Medicinal steroid use*ƚ 29 (23.7%) 258, 014, 001,106, 107, 015, 016, 183, 193, 353, 046, 081, 095 
NSAID*ƚ 28 (23%) 107, 258, 011, 103, 014, 174, 183,193, 020, 353, 004, 046, 056, 081, 084, 087 
Immunosupression 25 (20.5%) 014, 015, 046 , 258, 001,106, 116, 016,017, 183, 186, 193, 353 
Chemotherapy*ƚ 18 (14.7%) 046, 001, 106, 116, 014,183,186, 193, 216, 258,003, 353 
CKD 17 (14%) 011, 116,126, 014, 017, 174, 046, 078, 084 
CLD 5 (4.1%) 183, 186, 003 
Organ-transplant 4 (3.3%) 011 
IBD 1 (0.8%) 015, 056 
*PPI: Proton Pump Inhibitor; NSAID: Non-steroidal anti-inflammatory drug; IBD: Inflammatory bowel disease; CKD: Chronic kidney 
disease; CLD: Chronic liver disease. 
ƚAll treatments were administered up to 3 months prior to acquiring CDI. 
NS: Non-significant. 
Discussion 
Our study showed presence of CDI in 122 of the 1,532 patients (prevalence of 7.9% during 
the period 2011 to 2012; 6.4% of which were hospital acquired). Amongst the hospital 
acquired patients, 5.7% (n = 87/1,532) were from Hamad General Hospital and 0.7% (n = 
11/1,532) from Al Khor Hospital. The reason for the large difference between the hospitals is 
probably due to the presence of more patient samples, in our study, from Hamad General 
Hospital vs. Al Khor Hospital. Of the 122 CDI positive patients 98 (80.3%) had hospital 
acquired CDI and 14 (11.8%) had community-acquired CDI. The prevalence data found in 
our study are comparable to data from other Middle-Eastern countries (prevalence range 4.6-
13.7%; average ~8.6%) [14-18]. Comparatively, in Europe C. difficile infections are 
responsible for only 3.6% of all hospital acquired infections [19]. The difference may be 
attributed to over-prescription of antibiotics in the Middle East. However, it must be noted 
that the sample sizes used in this study and in the cited Middle Eastern studies are quite small 
compared to the large surveillance data gathered by the European surveillance study [19]. 
The key finding is that CDI appears to be doubled in patients in hospitals in the Middle East 
compared with Europe, and may be under-diagnosed . The difference in CDI illustrates the 
importance of active surveillance of CDI in hospitals in the Middle East and a need for 
regulation of antibiotic prescription. 
The PCR ribotypes predominant in Qatar during this period were 258 followed by 
001/014/046. The most common ribotypes isolated from two other countries in the Middle 
East were: 002, 001, 126 and 140 from Kuwait [16]; and 078 from Iran [20], respectively. 
However, there is very little data on other specific riborypes in the Middle East; whereas 
ribotypes 017, 018, 014, 002 and 001 have been shown to be most prevalent in Asia [21-25]. 
A study carried out by Bauer and colleagues in 34 European countries identified PCR 
ribotypes 014/020, 001, and 078 as the most prevalent in Europe [26]. The prevalence of 
PCR-ribotype 027 was only 5% in this study [26], although this ribotype had been previously 
associated with increasing outbreaks of CDI in hospitals in North America, Japan and Europe 
[27]. This ribotype was isolated from only one sample in the present study and was not 
isolated in either the Kuwaiti or Iranian studies mentioned earlier [16,20]. It is important to 
note here that we managed to culture only 79 samples successfully out of the 122 with CDI. 
This low number might have led to under-representation of PCR ribotypes that caused CDI in 
our patient population. 
The antibiotics most frequently correlating with CDI in our study were third generation 
cephalosporins and piperacillin/tazobactam. Third generation cephalosporins, even when 
administered as short-term perioperative prophylaxis, have been significantly associated with 
C. difficile-related diseases [28,29]. Piperacillin/tazobactam has also been linked to 
development of CDI, though tazocin is generally associated with lower risk of C. difficile 
infections [30,31]. The correlation of CDI with piperacillin/tazobactam in our study may 
reflect the over-prescribing of antibiotics in Qatar. The use of certain antibiotics, especially 
fluoroquinolones, has been previously associated with infection by PCR-ribotype 027 
[27,32]. In our study the ribotype most associated with third generation cephalosporins and 
piperacillin/tazobactam use was 258 in 6 patients (n = 2 and n = 4 for each antibiotic, 
respectively). 
In our study, CDI was most often correlated with older age (≥65 yrs) and use of PPIs. 
However, it must be noted that the number of infections for which these correlations were 
based was small. Old age and PPIs have been previously reported to be risk factor for CDI 
[33-35]. Controlled prescribing of PPIs, especially in high risk individuals, may be important 
in control of CDIs. No ribotype correlated significantly with any risk factor investigated. 
Unfortunately patient outcomes after confirmation of CDI were not investigated, which is a 
limitation of this study and needs to be addressed in future studies. Additional limitations 
include missing data for the 10 patients, which could not be classified in hospital-acquired or 
community-acquired CDI. These patients comprise 8.2% of the CDI positive population and 
their inclusion would have been useful here. Furthermore, in this study, we had small sample 
sizes for each age group and hence correlation of CDI with age will probably have to be 
repeated with larger samples. Overall, Qatar population is ~350,000 people and, although a 
relatively homogenous population, recruiting for clinical studies is limited by the small 
population size. Finally, while ribotype 027 was only identified in one sample, further 
surveillance is required to determine whether this strain is indeed present in the country and 
to monitor for its prevalence in a larger sample set. 
Conclusion 
The commonest C. difficile ribotype identified in Qatar was different from those found in 
North America, Europe and Asia. In addition, the prevalence of CDI was higher in Qatar than 
Europe; though comparable to other Middle Eastern countries. Restrictions on the use of 
antibiotics and PPIs should be considered in the Middle East. Unrestricted prescribing of 
medicine is complicated further by a lack of epidemiology data and surveillance of CDI in 
Middle-Eastern countries. These findings underscore the importance of local surveillance to 
detect and control C. difficile infection. The findings also highlight a need to control PPI 
prescriptions, especially in the elderly population. 
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